We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 15, 2021

Cutaneous Adverse Events in Patients With Metastatic Melanoma Consecutively Treated With Anti-CTLA4 and Anti–PD-1 Combination Immunotherapy

Cancer

 

Additional Info

Cancer
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
Cancer 2021 Nov 01;[EPub Ahead of Print], AB Patel, S Farooq, M Welborn, RN Amaria, SY Chon, A Diab, IC Glitza Oliva, AO Huen, SQ Li, KC Nelson, O Pacha, SP Patel, RP Rapini, HA Tawbi, MK Wong, J McQuade, MA Davies, LE Haydu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading